No headlines found.
No press releases found.
No news found.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Abvc Biopharma trades on the NASDAQ stock market under the symbol ABVC.
As of December 17, 2025, ABVC stock price declined to $2.04 with 7,792 million shares trading.
ABVC has a beta of 2.07, meaning it tends to be more sensitive to market movements. ABVC has a correlation of 0.14 to the broad based SPY ETF.
ABVC has a market cap of $48.03 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ABVC traded as high as $18.70 and as low as $.40.
The top ETF exchange traded funds that ABVC belongs to (by Net Assets): VXF.
ABVC has outperformed the market in the last year with a return of +300.0%, while the SPY ETF gained +12.2%. However, in the most recent history, ABVC shares have underperformed the stock market with its stock returning -28.2% in the last 3 month period and -20.0% for the last 2 week period, while SPY has returned +2.3% and -1.2%, respectively.
ABVC support price is $1.95 and resistance is $2.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVC shares will trade within this expected range on the day.
